News | March 31, 2026
Novo Nordisk India sets patient-centred price of Rs. 202/day for starting dose of Ozempic and Wegovy
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances
Call it a major breakthrough for diagnostic imaging
PreemieFort Enteral Solution's approval marks the first time a nutritional product derived from human milk has been recognized as a prescription medicine anywhere in the world
Company to launch product after the expiry of semaglutide patent in India
Applications include detailed scientific rationale and supporting clinical evidence
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
Subscribe To Our Newsletter & Stay Updated
